Reply to “Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin”

Juan Aguilar-Company,a Ibai Los-Arcos,a Carlos Pigrau,a,b Benito Almirantea,b
Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain

We thank Antonio Sorlózano-Puerto, José María Navarro-Mari, and José Gutiérrez-Fernández for their comment on our paper (1, 2) and greatly appreciate their data on fosfomycin susceptibility in Campylobacter species isolates. To our knowledge, this is the first report on Campylobacter species susceptibility to fosfomycin since 1995 (3). As we stated in the Discussion, data on rates of resistance to fosfomycin in Campylobacter spp. are scarce and “further studies are needed to establish MIC breakpoints and define resistance rates in different geographical areas”; therefore, any information is of great value. Given their findings, we emphasize that determining the MIC of fosfomycin is crucial previous to deciding on its use in the therapy of difficult-to-treat Campylobacter species infections.

REFERENCES

Copyright © 2017 American Society for Microbiology. All Rights Reserved.
Address correspondence to Juan Aguilar-Company, juanaguilarcompany@gmail.com, or Carlos Pigrau, cpigrau@vhebron.net.
This is a response to a letter by Sorlózano-Puerto et al. (https://doi.org/10.1128/AAC.02317-16).